Cancer-Treatment Isotope Supply to Increase from Landmark Deal Reached by GE Hitachi Nuclear Energy and Exelon Generation Company

WILMINGTON, N.C.--(BUSINESS WIRE)--Seeking to address a growing demand for the domestic and global supply of cobalt-60, a radioisotope used for treating cancer and other biomedical applications, GE Hitachi Nuclear Energy (GEH) and Exelon Generation Company have agreed to a landmark deal to deploy GEH’s isotope generation technology.
MORE ON THIS TOPIC